ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

MBRX Moleculin Biotech Inc

4.77
0.13 (2.80%)
31 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Moleculin Biotech Inc MBRX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.13 2.80% 4.77 23:00:02
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.64 4.64 4.87 4.77 4.64
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
16/5/202407:32EDGAR2Form 8-K - Current report
16/5/202407:32PRNUSMoleculin Abstract Accepted for Poster Presentation at the..
15/5/202407:38EDGAR2Form 8-K - Current report
15/5/202407:38PRNUSMoleculin Announces Commencement of NIH-Funded Phase 2..
14/5/202415:16EDGAR2Form 8-K - Current report
13/5/202409:53EDGAR2Form 8-K/A - Current report: [Amend]
13/5/202406:30EDGAR2Form 8-K - Current report
13/5/202406:30PRNUSMoleculin Reports First Quarter 2024 Financial Results and..
10/5/202415:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202407:30EDGAR2Form 8-K - Current report
09/5/202407:30PRNUSMoleculin Announces U.S. Patent Issue Notification for..
08/5/202407:45PRNUSMoleculin to Report First Quarter 2024 Financial Results on..
08/5/202407:31EDGAR2Form 8-K - Current report
07/5/202415:13EDGAR2Form 8-K - Current report
07/5/202407:55EDGAR2Form 8-K - Current report
07/5/202407:55PRNUSMoleculin Reports Higher AML Complete Remission (CR) Rates..
02/5/202408:00PRNUSMoleculin to Host Virtual AML Clinical Day Featuring..
01/5/202407:50PRNUSMoleculin Announces Formation of Scientific Advisory Board..
18/4/202407:30PRNUSEuropean Medicines Agency (EMA) Grants Orphan Drug..
10/4/202407:30PRNUSMoleculin Announces Presentation of Positive Data..
28/3/202409:45PRNUSMoleculin to Present at the MedInvest Biotech & Pharma..
27/3/202408:25PRNUSMoleculin to Participate in the Virtual Investor Lunch..
27/3/202408:05PRNUSMoleculin Announces U.S. Patent Issue Notification for..
25/3/202406:30PRNUSMoleculin Announces Positive Interim Data in Annamycin..
22/3/202415:05PRNUSMoleculin Reports Full Year 2023 Financial Results
20/3/202406:30PRNUSMoleculin to Report Full Year 2023 Financial Results on..
20/3/202406:15IHMARKETNEWSJPMorgan boosts dividends, Chipotle unveils 50:1 stock..
19/3/202415:30PRNUSMoleculin Announces Reverse Stock Split
12/3/202408:05PRNUSMoleculin to Present at the 36th Annual ROTH Conference
29/2/202407:30EDGAR2Form 8-K - Current report
22/2/202408:30EDGAR2Form 8-K - Current report
16/2/202416:19EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/2/202408:15EDGAR2Form 8-K - Current report
14/2/202415:36EDGAR2Form 8-K - Current report
14/2/202415:33EDGAR2Form 8-K - Current report
12/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
02/2/202416:05EDGAR2Form S-1 - General form for registration of securities under..
24/1/202407:50EDGAR2Form 8-K - Current report
24/1/202407:50PRNUSMoleculin Announces 2023 Year-End Annamycin Clinical Trials..
16/1/202416:00EDGAR2Form DEF 14A - Other definitive proxy statements
05/1/202416:15EDGAR2Form PRE 14A - Other preliminary proxy statements
05/1/202416:14EDGAR2Form 8-K - Current report
27/12/202306:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202316:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
21/12/202316:17EDGAR2Form 8-K - Current report
20/12/202320:16PRNUSMoleculin Announces Pricing of $4.5 Million Registered..
18/12/202307:55EDGAR2Form 8-K - Current report
11/12/202307:55EDGAR2Form 8-K - Current report
11/12/202307:50EDGAR2Form 8-K - Current report
11/12/202307:50PRNUSMoleculin Presents Positive Interim Data from Phase 1B/2..

Su Consulta Reciente

Delayed Upgrade Clock